$1,035.08
Value $102B
EQIX and NHI stock compared: price, dividend, valuation and results, from SEC filings.
$1,035.08
Value $102B
$61.92
Value $3.0B
Equinix (EQIX) has a market value of $102B and National Health Investors (NHI) $3.0B. Over the last year, with dividends, EQIX moved +36.3% and NHI -16.9%. The P/E is 61.7 for EQIX and 4.3 for NHI. Dividend yield: EQIX 1.99%, NHI 5.98%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
EQIX$102B
NHI$3.0B
EQIX is 34 times NHI
Revenue, 12 months
EQIX$10.1B
NHI$456M
EQIX is 22 times NHI
Net income, 12 months
EQIX$1.6B
NHI$697M
EQIX is 2.4 times NHI
Operating margin
EQIX22.5%
NHI–
ROIC
EQIX5.9%
NHI–
P/E
EQIX61.7
NHI4.3
EQIX is 14 times NHI
Dividend yield
EQIX2.0%
NHI6.0%
4.0 points apart
5-year return
EQIX+44.4%
NHI+45.0%
0.6 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
EQIX+44.4%
NHI+45.0%
| Period | EQIXWith dividends | NHIWith dividends |
|---|---|---|
| 1 year since November 18, 2025 | +36.3%Price +32.8% | -16.9%Price -20.9% |
| 3 years since November 17, 2023 | +42.3%+12.5% a yearPrice +33.6% | +34.4%+10.4% a yearPrice +15.4% |
| 5 years since November 18, 2021 | +44.4%+7.6% a yearPrice +30.6% | +45.0%+7.7% a yearPrice +9.2% |
| 10 years since November 21, 2016 | +273.4%+14.1% a yearPrice +208.1% | +56.1%+4.6% a yearPrice -11.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
EQIXEquinixNHINational Health Investors
| Price | $1,035.08 | $61.92 |
|---|---|---|
| Market value | $102B | $3.0B |
| Enterprise value (EV) | $123B | – |
| P/E | 61.7 | 4.3 |
| P/E, 5-year median | 78.1 | 23.6 |
| P/B | 7.0 | 1.4 |
| EV/EBIT | 54.5 | – |
| Free cash flow yield | – | – |
| Revenue, 12 months | $10.1B | $456M |
|---|---|---|
| Net income, 12 months | $1.6B | $697M |
| Free cash flow, 12 months | -$1.7B | -$57M |
| Earnings per share, 12 months | $16.65 | $14.24 |
| Revenue growth, year on year | 5.4% | 12.1% |
| Revenue growth a year, past | +9.0%over 5 years | +2.5%over 5 years |
| EPS growth a year, past | +26.9%over 5 years | -6.1%over 5 years |
| Gross margin | 51.6% | – |
|---|---|---|
| Operating margin | 22.5% | – |
| Net margin | 16.4% | 153.0% |
| ROIC | 5.9% | – |
| ROE | 11.5% | 42.6% |
| Cash | $3.6B | $278M |
|---|---|---|
| Total debt | $26.6B | $1.1B |
| Net debt / EBITDA | 5.0 | – |
| Interest cover | 3.8× | – |
| Dividend yield | 2.0% | 6.0% |
|---|---|---|
| Dividend per share, 12 months | $20.64 | $3.70 |
| Dividend growth a year, past | +12.0%over 5 years | -3.6%over 5 years |
| Buyback yield | – | – |
| Shareholder yield | 2.0% | 6.0% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Equinix ($102B) is about 33.9 times National Health Investors ($3.0B), at today's prices.
Since November 21, 2016, EQIX's price moved +208.1% and NHI's -11.7%. With dividends: EQIX +273.4% (+14.1% a year), NHI +56.1% (+4.6% a year). Past returns do not predict future ones.
The dividend yield at today's price is 1.99% for Equinix and 5.98% for National Health Investors. Over the last twelve months they paid $20.64 and $3.70 per share.
At today's price, the P/E is 61.7 for EQIX and 4.3 for NHI. The median of the last five years was 78.1 and 23.6, which shows where each stands against its own past.
Over the last twelve months, the net margin was 16.4% for Equinix and 153.0% for National Health Investors, and the operating margin 22.5% and –. Revenue was $10.1B and $456M.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.